REFERENCES
- Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):240–245.
- Hughes WT, Armstrong D, Bodey GP, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751.
- Jones RN, Pfaller MA, Fuchs PC, Piperacillin/tazobactam (YTR 830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteriodes fragilis group strains. Diagn Microb Infect Dis. 1989;12:489–494.
- Payne DJ, Cramp R, Winstanley DJ, Comparative activities of clavulonic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother. 1994;38:767–772.
- Jones GR, Konslet GK, Pusek SN. Infection risk factors in febrile neutropenic children and adolescent. Pediatric Hematol Oncol. 1996;13:217–229.
- Hakim H, Flynn PM, Knapp M, Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009;31:623–629.
- Le Guyader N, Auvrignon A, Vu-Thien H, Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer. 2004;12:720–724.
- Kobayashi R, Sato T, Nakajima M, Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol. 2009;31:270–273.
- Greenberg D, Moser A, Yagupsky P, Microbiological spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469–473.
- Hamidah A, Rizal AM, Nordiah AJ, Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in pediatric cancer patients. Singapore Med J. 2008;49:26–30.
- Aksoylar S, Çetingül N, Kantar M, Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empirical therapy for high risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004;21:115–123.
- Vural S, Erdem E, Geylani Güleç S, Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262–267.
- Çorapcioğlu F, Sarper N. Cefepime versus ceftazidime+amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005;22:59–70.
- Çorapcioğlu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patient: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177–186.
- Paul M, Soares-Weiser K, Grozinsky S, Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2003;(3):CD003038.
- Simon A, Lehrnbecher T, Bode U, Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbial Infect Dis. 2007;26:801–806.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbial Rev. 2005;18:657–686.
- EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987;317:1692–1698.
- Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231–242.
- Meunier F, Lukan C. The first European Conference on Infections in Leukaemia—ECIL1: a current perspective. Eur J Cancer. 2008;44:2112–2117.
- Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs. 2003;4:974–990.
- Goldberg E, Gafter-Gvili A, Robenshtok E, Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer. 2008;44:2192–2203.
- Maertens J, Theunissen K, Verhoef G, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–1250.